KenOliveLab Profile Banner
KenOliveLab Profile
KenOliveLab

@KenOliveLab

Followers
4K
Following
2K
Media
265
Statuses
3K

Asc Prof. of Medicine, Columbia University, views own. Pancreatic cancer, translational therapeutics, metabolism, systems, paracrine interactions. It all fits.

New York, NY, USA
Joined August 2018
Don't wanna be here? Send us removal request.
@KenOliveLab
KenOliveLab
1 year
OK, this one is really meaningful for our whole team. Our preclinical paper on pan-RAS inhibition in pancreatic cancer is now online @Nature. Led by OliveLab student @ulawasko and Revolution Medicines colleagues JingJing Jiang and Mallika Singh.
19
57
216
@KenOliveLab
KenOliveLab
8 months
Sad to miss the first #PCAMChat24. Briefly, this is Ken Olive from @columbiacancer. I lead a translational research lab dedicated to #PDAC research. Excited to join in for part 2!.
0
0
7
@KenOliveLab
KenOliveLab
8 months
Suddenly seeing a huge number of fellow scientists show up on BlueSky. FYI I'm one of them. Come follow me: @kenolivelab.bsky.social.
2
0
2
@KenOliveLab
KenOliveLab
8 months
RT @Aiims1742: ICYMI, the new issue of @CR_AACR is online and features the print version of the In Focus commentary .#PancreaticCancer–Asso….
0
15
0
@KenOliveLab
KenOliveLab
9 months
New post on our website with updated information on the clinical development of RAS inhibitors for pancreatic cancer. I'll summarize on twitter sooner, but here's the full version:
1
14
41
@KenOliveLab
KenOliveLab
9 months
RT @BHenickMD: On behalf of our Phase I program @columbiacancer , proud of @bherzbergmd presenting exciting initial data on IDE397 in MTAP-….
0
6
0
@KenOliveLab
KenOliveLab
9 months
Really excited for my postdoc @MC_Hasselluhn who received a 4th percentile score on her K99 application. Folks, she's on the job market!.
10
1
67
@KenOliveLab
KenOliveLab
9 months
RT @Aiims1742: Revolution Medicines has launched its ph 3 study of RMC-6236 (RASolute 302) in patients with previously treated #PancreaticC….
0
54
0
@KenOliveLab
KenOliveLab
10 months
RT @simonduerr: There is a new tool on BioIcons to turn any protein (in PDB format) into a 2D vector illustration in SVG format. You can up….
0
174
0
@KenOliveLab
KenOliveLab
10 months
RT @columbiacancer: We are thrilled to welcome Michel Sadelain, MD, PhD, a global pioneer in CAR-T therapies, to Columbia and the HICCC.
0
7
0
@KenOliveLab
KenOliveLab
10 months
RT @ARNesLab: I am excited to see this story by my talented Master's Student, Kristina Høj. Her research dives into age-related decline in….
0
2
0
@KenOliveLab
KenOliveLab
10 months
RT @Aiims1742: New online perspective article @CR_AACR article timed with the ongoing #PancreaticCancer stroma session at #AACRPan24 .Pancr….
0
14
0
@KenOliveLab
KenOliveLab
11 months
Hiring committees take note. .
@AlvaroCurielGa1
Alvaro Curiel-García, PhD
11 months
That feeling when you submit your first application for a tenure-track faculty! 🧑‍🔬 I am planing to create a "Translational systems oncology" laboratory focused on cell states, hypoxia and targeted therapies where I will use both wet and dry approaches. #faculty #academiclife.
0
0
9
@KenOliveLab
KenOliveLab
11 months
RT @cudldrc: Congratulations to CU-DLDRC Associate Director, Timothy Wang, MD, who is the new Vice Chair for Academic Programs for the Depa….
0
1
0
@KenOliveLab
KenOliveLab
11 months
RT @zeribechike: @NwosuLab @CornellMBG has opened a call for postdoc applicants. Please kindly repost and or forward to potential applicant….
0
9
0
@KenOliveLab
KenOliveLab
11 months
RT @GabreJoel: Proud to have helped launch the Columbia Early Onset Colorectal Cancer Program @columbiacancer @nyp with @BDionigiMD and Yo….
0
4
0
@KenOliveLab
KenOliveLab
11 months
When everything is urgent, nothing is urgent.
0
1
9
@KenOliveLab
KenOliveLab
11 months
The Olive Lab is looking for a postdoc to lead our translational program on RAS inhibition in pancreatic cancer. Should have exceptional scientific and project management skills, and experience with transdisciplinary research. Must be a good human.
2
38
83
@KenOliveLab
KenOliveLab
1 year
Really exciting times for the PDAC field, offering real hope for patients. This is just monotherapy. Can't wait to see combinations!.
0
1
14
@KenOliveLab
KenOliveLab
1 year
Data available on their website at:
1
2
8
@KenOliveLab
KenOliveLab
1 year
They present a preliminary design of a planned Phase 3 trial in 2nd line PDAC patients, randomized to physician's choice.
Tweet media one
2
2
10